# Alexis Dormandy

> Alexis Dormandy is a funding round investor at Oxford Science Enterprises backing Medical. See 1 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oxford Science Enterprises](https://shizune.co/investors/profile/oxford-sciences-innovation)
- Location: London, United Kingdom
- Total investments: 1
- Last investment: Aug 2021
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/in/alexisdormandy
- X (Twitter): http://twitter.com/adormandy
- Website: https://x.com/adormandy

Alexis Dormandy is a funding round investor at Oxford Science Enterprises in London focused on Medical and Biotechnology. Alexis is a Partner at Atomico, where he helps portfolio companies with their growth strategy and scaling, and evaluates new investment opportunities. He works closely with companies across Europe and the US including Messagebird, Teralytics, Framer, and Hinge Health. He is based in London.Alexis spent his early career at Virgin and was afounding Director at both Virgin Mobile and Virgin Active. Alexis then became VP Consumer and Chief Marketing Officer at Orange, during which time the firm grew to become #1 mobile operator in the UK. He then moved to Candover, a large European private equity firm, and served as European Chairman of RED, the AIDS charity founded by Bono. He is currently Chairman of Wattbike, the world’s most advanced indoor bike.Having originally trained as a doctor, Alexis has become the first port-of-call for all those at Atomico feeling the Monday morning strain after a weekend of bike riding and marathon running.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 1 | 100% |
| Biotechnology | 1 | 100% |
| Clinical Trials | 1 | 100% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Pepgen | PepGen empowers nucleic acid therapeutics to go the distance. PepGen's ambition is to unlock the potential of nucleic acid therapeutics by leveraging the drug delivery capabilities of their innovative product engine. PepGen's initial focus is on the application of this technology to the efficacious delivery of antisense oligonucleotides,and they are advancing novel conjugate therapeutics to the clinic. | $112.5M |  | Aug 05, 2021 |  |

1 of 1 investments shown.

## Co-investors
- [Adage Capital Management](https://shizune.co/investors/profile/adage-capital-management) — VC Fund, 1 deal together
- [CureDuchenne Ventures](https://shizune.co/investors/profile/cureduchenne-ventures) — VC Fund, 1 deal together
- [Deerfield](https://shizune.co/investors/profile/deerfield) — VC Fund, 1 deal together
- [Deerfield Management](https://shizune.co/investors/profile/deerfield-management-83d0) — VC Fund, 1 deal together
- [Gray’s Creek Capital Partners](https://shizune.co/investors/profile/gray-s-creek-capital-partners) — VC Fund, 1 deal together
- [Laurion Capital Management](https://shizune.co/investors/profile/laurion-capital-management) — VC Fund, 1 deal together

## About Oxford Science Enterprises

VC Fund · Oxford, United Kingdom

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

5 contacts available at Oxford Science Enterprises.

| Name | Title | Profile |
| --- | --- | --- |
| Alexis Dormandy | Chief Executive Officer | https://shizune.co/investors/profile/alexis-dormandy |
| Alexis Zervoglos | Senior Partner (Technology) | https://shizune.co/investors/profile/alexis-zervoglos |
| Claire Brown | Partner ( Life Sciences) | https://shizune.co/investors/profile/claire-brown |
| Ekaterina Smirnyagina | Senior Partner and Head of Life Sciences | https://shizune.co/investors/profile/ekaterina-smirnyagina |
| David Norwood | Chairman | https://shizune.co/investors/profile/david-norwood |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Alexis Dormandy invest in?

Alexis Dormandy invests primarily in Medical, Biotechnology and Clinical Trials startups, most often at Funding Round stage. Most of the 1 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Alexis Dormandy last invest?

The most recent investment recorded for Alexis Dormandy closed in Aug 2021. Shizune tracks 1 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co